Evidence map›Paper›PMID 42669628›Full record

ArticleThe Journal of antimicrobial chemotherapy2026

Group A Streptococcus molecular point of care testing in a paediatric emergency department.

Ewurabena A Mills, Rebekah Bingham, Ruud G Nijman, Shiranee Sriskandan

Abstract read
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ewurabena A MillsDepartment of Infectious Disease, Imperial College London, London, UK.
Rebekah BinghamDepartment of Infectious Disease, Imperial College London, London, UK.
Ruud G NijmanDepartment of Infectious Disease, Imperial College London, London, UK.
Shiranee SriskandanDepartment of Infectious Disease, Imperial College London, London, UK.ORCID 0000-0002-5214-4941

Funding

ICHT Charity Fellowship to E.MNIHR Health Protection UnitNIHR HPRU
6 · The paper itself

Abstract

backgroundAn upsurge in Streptococcus pyogenes infections 2022-2023 highlighted potential benefits of point-of-care tests (POCT) to support clinical pathways, prevent outbreaks and optimize antibiotic use.

objectivesWe conducted a pilot research study in a west London paediatric emergency department (ED) to determine whether a molecular POCT had potential to alter management in children who were also having a conventional throat swab taken for culture.

methodsChildren <16 years presenting to ED who had a throat swab requested by a clinician were invited to have a second swab taken for research purposes only. Clinical management was unaffected by the research swab result, which was processed using a molecular POCT that was not approved for use in the host NHS Trust.

resultsPrevalence of streptococcal infection was low during the study (May 2023-June 2025); swab positivity in symptomatic children was 12.8% (6/47). Overall, 38/49 (77.6%) participants who had throat swabs received antibiotics. Of those children recommended to receive antibiotics, 29/38 (76.3%) had a negative POCT. Mean time to reporting of positive throat swab culture results was 3.67 days (range 3-5 days) leading to occasional delay in treatment, although POCT identified positive results within minutes.

conclusionAntibiotic use was frequent and could be avoided by use of a 'rule out' POCT in many children in the ED, provided suspicion of S. pyogenes is the main driver for prescribing. POCT were easy to process and produced immediate results compared with culture. More research is needed to establish whether POCT confers overall net benefit.

Indexed as

Emergency Service, HospitalPoint-of-Care TestingStreptococcal InfectionsStreptococcus pyogenesAdolescentAnti-Bacterial AgentsChildChild, PreschoolFemaleHumansInfantLondonMalePharynxPilot ProjectsPrevalenceAnti-Bacterial Agents

Identifiers

PMID42669628
PMCPMC13526505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.